Research Analysts Issue Forecasts for PRQR FY2025 Earnings

Key Points

• HC Wainwright has revised down its FY2025 earnings per share estimate for ProQR Therapeutics to ($0.45), down from ($0.41), while the consensus estimate for the current year stands at ($0.31) per share.
• ProQR Therapeutics reported a loss of ($0.14) per share for the last quarter, missing analyst expectations by ($0.06), with revenue of $4.33 million falling short of estimates of $5.01 million.
• The stock has experienced a recent trading range between a 12-month low of $1.07 and a high of $4.62, opening at $2.21 on Thursday.

ProQR Therapeutics N.V. (NASDAQ:PRQR - Free Report) - Equities researchers at HC Wainwright dropped their FY2025 earnings per share estimates for ProQR Therapeutics in a report released on Monday, August 25th. HC Wainwright analyst A. Fein now forecasts that the biopharmaceutical company will post earnings of ($0.45) per share for the year, down from their previous estimate of ($0.41). The consensus estimate for ProQR Therapeutics' current full-year earnings is ($0.31) per share.

PRQR has been the subject of a number of other research reports. Chardan Capital reiterated a "buy" rating and set a $4.00 price target on shares of ProQR Therapeutics in a report on Friday, August 8th. Cantor Fitzgerald restated an "overweight" rating and set a $8.00 price objective on shares of ProQR Therapeutics in a research report on Friday, June 27th. Evercore ISI reaffirmed an "outperform" rating on shares of ProQR Therapeutics in a report on Friday, July 11th. JMP Securities reaffirmed a "market outperform" rating and set a $8.00 target price on shares of ProQR Therapeutics in a report on Friday, June 27th. Finally, Oppenheimer dropped their price objective on ProQR Therapeutics from $15.00 to $9.00 and set an "outperform" rating on the stock in a research note on Tuesday, May 13th. One equities research analyst has rated the stock with a Strong Buy rating and seven have issued a Buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of "Buy" and a consensus target price of $8.00.

ProQR Therapeutics Trading Down 0.2%

Shares of NASDAQ:PRQR traded down $0.01 during midday trading on Thursday, hitting $2.25. The company had a trading volume of 119,191 shares, compared to its average volume of 416,393. The stock has a market cap of $236.20 million, a price-to-earnings ratio of -4.88 and a beta of 0.36. ProQR Therapeutics has a 12 month low of $1.07 and a 12 month high of $4.62. The firm has a fifty day simple moving average of $2.17 and a 200 day simple moving average of $1.87.

ProQR Therapeutics (NASDAQ:PRQR - Get Free Report) last posted its earnings results on Thursday, August 7th. The biopharmaceutical company reported ($0.14) earnings per share for the quarter, missing the consensus estimate of ($0.08) by ($0.06). The company had revenue of $4.33 million for the quarter, compared to the consensus estimate of $5.01 million. ProQR Therapeutics had a negative net margin of 238.52% and a negative return on equity of 61.25%.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the stock. JPMorgan Chase & Co. lifted its holdings in shares of ProQR Therapeutics by 17,707.7% in the fourth quarter. JPMorgan Chase & Co. now owns 53,423 shares of the biopharmaceutical company's stock valued at $142,000 after purchasing an additional 53,123 shares in the last quarter. Invesco Ltd. bought a new position in shares of ProQR Therapeutics in the 4th quarter worth about $32,000. Raymond James Financial Inc. acquired a new stake in shares of ProQR Therapeutics in the 4th quarter valued at about $260,000. Marshall Wace LLP purchased a new position in shares of ProQR Therapeutics in the 4th quarter worth approximately $158,000. Finally, Two Sigma Securities LLC purchased a new position in shares of ProQR Therapeutics in the 4th quarter worth approximately $40,000. 32.65% of the stock is currently owned by institutional investors.

ProQR Therapeutics Company Profile

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1).